Head-to-head evidence
QiShenYiQi vs Shenfu injection
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Heart Failure
Shared mechanism: Multi-target (ginsenoside) · full Heart Failure pipeline
QiShenYiQi
Developed by Tasly Pharmaceutical Group
NCT04944706 · Phase 2 · completed
The study was randomized and quadruple-blinded, with two QiShenYiQi dose groups and a placebo group, and enrolled 225 participants. Its primary clinical functional endpoint was 6-minute walking distance, but whether that endpoint was met cannot be determined because results are not posted.
Next expected readout: December 2026 · NCT06699407 (registry estimate)
Shenfu injection · Shenfu Zhusheye
Marketed by China Resources Sanjiu Medical & Pharmaceutical
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: QiShenYiQi's landscape · Shenfu injection's landscape